Pfizer Gross Profit 2012-2026 | PFE
Pfizer annual/quarterly gross profit history and growth rate from 2012 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Pfizer gross profit for the quarter ending March 31, 2026 was $10.903B, a 0.3% increase year-over-year.
- Pfizer gross profit for the twelve months ending March 31, 2026 was $46.545B, a 3.1% increase year-over-year.
- Pfizer annual gross profit for 2025 was $46.512B, a 1.61% increase from 2024.
- Pfizer annual gross profit for 2024 was $45.776B, a 32.3% increase from 2023.
- Pfizer annual gross profit for 2023 was $34.599B, a 48.23% decline from 2022.
|
Pfizer Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $46,512 |
| 2024 | $45,776 |
| 2023 | $34,599 |
| 2022 | $66,831 |
| 2021 | $50,467 |
| 2020 | $33,167 |
| 2019 | $32,851 |
| 2018 | $31,838 |
| 2017 | $41,318 |
| 2016 | $40,502 |
| 2015 | $39,203 |
| 2014 | $40,028 |
| 2013 | $41,998 |
| 2012 | $44,836 |
| 2011 | $48,535 |
|
Pfizer Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2026-03-31 | $10,903 |
| 2025-12-31 | $12,285 |
| 2025-09-30 | $12,482 |
| 2025-06-30 | $10,875 |
| 2025-03-31 | $10,870 |
| 2024-12-31 | $11,854 |
| 2024-09-30 | $12,439 |
| 2024-06-30 | $9,983 |
| 2024-03-31 | $11,500 |
| 2023-12-31 | $7,007 |
| 2023-09-30 | $4,222 |
| 2023-06-30 | $9,770 |
| 2023-03-31 | $13,600 |
| 2022-12-31 | $15,485 |
| 2022-09-30 | $16,575 |
| 2022-06-30 | $19,094 |
| 2022-03-31 | $15,677 |
| 2021-12-31 | $14,102 |
| 2021-09-30 | $14,103 |
| 2021-06-30 | $11,903 |
| 2021-03-31 | $10,359 |
| 2020-12-31 | $8,716 |
| 2020-09-30 | $8,270 |
| 2020-06-30 | $8,038 |
| 2020-03-31 | $8,143 |
| 2019-12-31 | $1,400 |
| 2019-09-30 | $10,078 |
| 2019-06-30 | $10,688 |
| 2019-03-31 | $10,685 |
| 2018-12-31 | $341 |
| 2018-09-30 | $10,604 |
| 2018-06-30 | $10,550 |
| 2018-03-31 | $10,343 |
| 2017-12-31 | $10,447 |
| 2017-09-30 | $10,324 |
| 2017-06-30 | $10,236 |
| 2017-03-31 | $10,311 |
| 2016-12-31 | $10,415 |
| 2016-09-30 | $9,960 |
| 2016-06-30 | $9,973 |
| 2016-03-31 | $10,154 |
| 2015-12-31 | $10,636 |
| 2015-09-30 | $9,868 |
| 2015-06-30 | $9,673 |
| 2015-03-31 | $9,026 |
| 2014-12-31 | $10,416 |
| 2014-09-30 | $9,993 |
| 2014-06-30 | $10,311 |
| 2014-03-31 | $9,308 |
| 2013-12-31 | $10,764 |
| 2013-09-30 | $10,356 |
| 2013-06-30 | $10,731 |
| 2013-03-31 | $10,147 |
| 2012-12-31 | $10,460 |
| 2012-09-30 | $10,644 |
| 2012-06-30 | $11,592 |
| 2012-03-31 | $12,140 |
| 2011-12-31 | $9,612 |
| 2011-09-30 | $13,200 |
| 2011-06-30 | $12,914 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |